Pharmaceutical care issues identified by pharmacists in patients with diabetes, hypertension or hyperlipidaemia in primary care settings

Siew Siang Chua, Li Ching Kok, Faridah Aryani Md Yusof, Guang Hui Tang, Shaun Wen Huey Lee, Benny Efendie, Thomas Paraidathathu, Siew Siang Chua, Li Ching Kok, Faridah Aryani Md Yusof, Guang Hui Tang, Shaun Wen Huey Lee, Benny Efendie, Thomas Paraidathathu

Abstract

Background: The roles of pharmacists have evolved from product oriented, dispensing of medications to more patient-focused services such as the provision of pharmaceutical care. Such pharmacy service is also becoming more widely practised in Malaysia but is not well documented. Therefore, this study is warranted to fill this information gap by identifying the types of pharmaceutical care issues (PCIs) encountered by primary care patients with diabetes mellitus, hypertension or hyperlipidaemia in Malaysia.

Methods: This study was part of a large controlled trial that evaluated the outcomes of multiprofessional collaboration which involved medical general practitioners, pharmacists, dietitians and nurses in managing diabetes mellitus, hypertension and hyperlipidaemia in primary care settings. A total of 477 patients were recruited by 44 general practitioners in the Klang Valley. These patients were counselled by the various healthcare professionals and followed-up for 6 months.

Results: Of the 477 participants, 53.7% had at least one PCI, with a total of 706 PCIs. These included drug-use problems (33.3%), insufficient awareness and knowledge about disease condition and medication (20.4%), adverse drug reactions (15.6%), therapeutic failure (13.9%), drug-choice problems (9.5%) and dosing problems (3.4%). Non-adherence to medications topped the list of drug-use problems, followed by incorrect administration of medications. More than half of the PCIs (52%) were classified as probably clinically insignificant, 38.9% with minimal clinical significance, 8.9% as definitely clinically significant and could cause patient harm while one issue (0.2%) was classified as life threatening. The main causes of PCIs were deterioration of disease state which led to failure of therapy, and also presentation of new symptoms or indications. Of the 338 PCIs where changes were recommended by the pharmacist, 87.3% were carried out as recommended.

Conclusions: This study demonstrates the importance of pharmacists working in collaboration with other healthcare providers especially the medical doctors in identifying and resolving pharmaceutical care issues to provide optimal care for patients with chronic diseases.

Trial registration: ClinicalTrials.gov NCT00490672.

Figures

Figure 1
Figure 1
Flow chart of the CORFIS study.

References

    1. Hepler C, Strand L. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990;47:533–543.
    1. van Mil F. Drug-related problems: a cornerstone for pharmaceutical care. J Malta College Pharm Pract. 2005;10:5–8.
    1. Pharmaceutical Care Network Europe (PCNE) Foundation. PCNE classification for drug related problems. (revised 01-05-06 vm) V5.01; 2006 .
    1. Krska J, Jamieson D, Arris F, McGuire A, Abbott S, Hansford D. et al.A classification system for issues identified in pharmaceutical care practice. Int J Pharm Pract. 2002;10:91–100. doi: 10.1111/j.2042-7174.2002.tb00593.x.
    1. Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc. 2001;41::192–199.
    1. Wermeille J, Bennie M, Brown I, McKnight J. Pharmaceutical care model for patients with type 2 diabetes: integration of the community pharmacist into the diabetes team: a pilot study. Pharm World Sc. 2004;26:18–25.
    1. Davis TM, Clifford RM, Davis WA, Batty KT. The role of pharmaceutical care in diabetes management. Brit J Diabet Vasc Dis. 2005;5:352–356. doi: 10.1177/14746514050050061001.
    1. Borges A, Guidoni C, Ferreira L, Freitas OD, Pereira L. The Pharmaceutical care of patients with type 2 diabetes mellitus. Pharm World Sc. 2010;32(6):730–736. doi: 10.1007/s11096-010-9428-3.
    1. Jameson JP, Baty PJ. Pharmacist collaborative management of poorly controlled diabetes mellitus: a randomized controlled trial. Am J Manag Care. 2010;16(4):250–255.
    1. Krass I, Armour CL, Mitchell B, Brillant M, Dienaar R, Hughes J. et al.Pharmacy diabetes care program: assessment of a community pharmacy diabetes service model in Australia. Diabet Med. 2007;24:677–683. doi: 10.1111/j.1464-5491.2007.02143.x.
    1. Mehuys E, Van Bortel L, De Bolle L, Van Tongelen I, Annemans L, Remon JP. et al.Effectiveness of a community pharmacist intervention in diabetes care: a randomized controlled trial. J Clin Pharm Ther. 2011;36(5):602–613. doi: 10.1111/j.1365-2710.2010.01218.x.
    1. Scott DM, Boyd ST, Stephan M, Augustine SC, Reardon TP. Outcomes of pharmacist-managed diabetes care service in a community health centre. Am J Health Syst Pharm. 2006;63:2116–2122. doi: 10.2146/ajhp060040.
    1. Royal S, Smeaton L, Avery A, Hurwitz B, Sheik A. Interventions in primary care to reduce medication related adverse events and hospital admissions: systematic review and meta analysis. Qual Saf Health Care. 2006;15:23–31. doi: 10.1136/qshc.2004.012153.
    1. Armour CL, Taylor SJ, Hourihan F, Smith C, Krass I. Implementation and evaluation of Australian pharmacists’ diabetes care services. J Am Pharm Assoc. 2004;44:456–466.
    1. Choe HM, Mitrovich S, Dubay D, Hayward RA, Krein SL, Vijan S. Proactive case management of high-risk patients with type 2 diabetes mellitus by a clinical pharmacist: a randomized controlled trial. Am J Manag Care. 2005;11:253–260.
    1. Clifford RM, Batty KT, Davis TME, Davis W, Stein G, Stewart G. et al.A randomised controlled trial of a pharmaceutical care programme in high-risk diabetic patients in an outpatient clinic. Int J Pharm Pract. 2002;10:85–89. doi: 10.1111/j.2042-7174.2002.tb00592.x.
    1. Davidson MB, Karlan VJ, Hair TL. Effect of a pharmacist-managed diabetes care program in a free medical clinic. Am J Med Qual. 2000;15:137–142. doi: 10.1177/106286060001500403.
    1. Irons BK, Lenz RJ, Anderson SL, Wharton B, Habeger B, Anderson G. Retrospective cohort analysis of the clinical effectiveness of a physician-pharmacist collaborative drug therapy management diabetes clinic. Pharmacotherapy. 2002;22:1294–1300. doi: 10.1592/phco.22.15.1294.33476.
    1. Jaber L, Halapy H, Fernet M, Tummalapalli S, Diwakaran H. Evaluation of a pharmaceutical care model on diabetes management. Ann Pharmacother. 1996;30:238–243.
    1. Rothman RL, Malone R, Bryan B. A randomized trial of a primary care-based disease management program to improve cardiovascular risk factors and glycated hemoglobin levels in patients with diabetes. Am J Med. 2005;118:276–284. doi: 10.1016/j.amjmed.2004.09.017.
    1. Stubbs J, Haw C, Cahill C. Auditing prescribing errors in a psychiatric hospital. Are pharmacists’ interventions effective? Hosp Pharm. 2004;11:203–206.
    1. Altman DG. Practical Statistics for Medical Research. 1. United States: Chapman & Hall/CRC; 1999.
    1. The Joint Formulary Committee. British National Formulary (BNF) 63. London: BMJ Group and Pharmaceutical Press; 2012.
    1. MICROMEDEX® 1.0. Drug Interactions. Thomson Reuters (Healthcare) Inc; . (accessed February 20, 2010)
    1. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: A randomized controlled trial. JAMA. 2006;296:2563–2571. doi: 10.1001/jama.296.21.joc60162.
    1. Gæde P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580–591. doi: 10.1056/NEJMoa0706245.
    1. UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703–713. doi: 10.1136/bmj.317.7160.703.
    1. McLean DL, McAlister FA, Johnson JA, King KM, Makowsky MJ, Jones CA. et al.A randomized trial of the effect of community pharmacist and nurse care on improving blood pressure management in patients with diabetes mellitus: study of cardiovascular risk intervention by pharmacists-hypertension (SCRIP-HTN) Arch Intern Med. 2008;168:2355–2361. doi: 10.1001/archinte.168.21.2355.
    1. Cohen LB, Taveira TH, Khatana SAM, Dooley AG, Pirraglia PA, Wu W-C. Pharmacist-led shared medical appointments for multiple cardiovascular risk reduction in patients with type 2 diabetes. Diabetes Educ. 2011;37(6):801–812. doi: 10.1177/0145721711423980.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する